Medical Devices was Petros Pharmaceuticals’s largest segment in fiscal 2022, bringing in $3.26M of $5.99M (54%).
| Segment | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|
| Prescription Medications | — | $4.61M | $2.73M |
| Prescription Medication Sales | $6.36M | — | — |
| Medical Devices | — | $3.21M | $3.26M |
| Medical Device Sales | $3.20M | — | — |
| Total | $9.56M | $7.81M | $5.99M |
Petros Pharmaceuticals brought in $5.99M from its two segments in fiscal 2022, the year ended December 31, 2022. That was down 23.3% from $7.81M in fiscal 2021. Medical Devices was the largest at $3.26M (54.4%), ahead of Prescription Medications at $2.73M (45.6%).
Compared with fiscal 2021, Medical Devices grew 1.6% to $3.26M, while Prescription Medications fell 40.6% to $2.73M.
Petros Pharmaceuticals began breaking out Prescription Medications in fiscal 2021 and Medical Devices in fiscal 2021. Petros Pharmaceuticals stopped reporting Prescription Medication Sales ($6.36M in fiscal 2020) and Medical Device Sales ($3.20M in fiscal 2020) as separate segments.
United States was Petros Pharmaceuticals’s largest region in fiscal 2022, bringing in $4.80M of $5.99M (80%).
| Geography | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|
| United States | $8.56M | $6.57M | $4.80M |
| International | $1.00M | $1.24M | $1.19M |
| Total | $9.56M | $7.81M | $5.99M |
Petros Pharmaceuticals brought in $5.99M from its two regions in fiscal 2022, the year ended December 31, 2022. That was down 23.3% from $7.81M in fiscal 2021. United States was the largest at $4.80M (80.1%), ahead of International at $1.19M (19.9%).
Compared with fiscal 2021, International fell 3.7% to $1.19M and United States fell 27.0% to $4.80M. From fiscal 2020 to 2022, combined revenue from these regions fell from $9.56M to $5.99M, a compound annual decline of 20.8%. United States' share of the total fell from 89.5% to 80.1%.
Petros Pharmaceuticals (PTPI) reports its revenue by segment and by geography. In fiscal 2022, Medical Devices was its largest segment, bringing in $3.26M (54.4% of the total), followed by Prescription Medications at $2.73M (45.6%).
Medical Devices was Petros Pharmaceuticals' largest segment in fiscal 2022, bringing in $3.26M, or 54.4% of the $5.99M total across its two segments.
United States was Petros Pharmaceuticals' largest region in fiscal 2022, bringing in $4.80M, or 80.1% of the $5.99M total across its two regions.
Medical Devices grew faster than Prescription Medications in fiscal 2022, up 1.6% from $3.21M to $3.26M. Prescription Medications fell 40.6% to $2.73M.
Every figure comes from Petros Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Petros Pharmaceuticals gives it, and years follow its fiscal calendar.
Petros Pharmaceuticals' revenue by segment goes back to fiscal 2020, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.